Insmed Stock Buy Hold or Sell Recommendation
| INSM Stock | USD 26.17 0.17 0.65% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Insmed Inc is 'Strong Buy'. Macroaxis provides Insmed buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Insmed positions. The advice algorithm takes into account all of Insmed's available fundamental, technical, and predictive indicators you will find on this site.
Real Value 30.94 | Target Price 42.42 | Hype Value 26.22 | Market Value 26.17 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Insmed Inc given historical horizon and risk tolerance towards Insmed. When Macroaxis issues a 'buy' or 'sell' recommendation for Insmed Inc, the advice is generated through an automated system that utilizes algorithms and statistical models.
Insmed |
Execute Insmed Buy or Sell Advice
The Insmed recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Insmed Inc. Macroaxis does not own or have any residual interests in Insmed Inc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Insmed's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Insmed Trading Alerts and Improvement Suggestions
| The company reported the previous year's revenue of 245.36 M. Net Loss for the year was (481.53 M) with profit before overhead, payroll, taxes, and interest of 190.23 M. | |
| Insmed Inc currently holds about 554.87 M in cash with (400.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62. | |
| Insmed Inc has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Insmed Insiders Sold US1.9m Of Shares Suggesting Hesitancy - Simply Wall St |
Insmed Returns Distribution Density
The distribution of Insmed's historical returns is an attempt to chart the uncertainty of Insmed's future price movements. The chart of the probability distribution of Insmed stock daily returns describes the distribution of returns around its average expected value. We use Insmed Inc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Insmed returns is essential to provide solid investment advice for Insmed.
| Mean Return | 0.39 | Value At Risk | -2.4 | Potential Upside | 3.84 | Standard Deviation | 2.73 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Insmed historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Insmed Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Insmed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Insmed Inc backward and forwards among themselves. Insmed's institutional investor refers to the entity that pools money to purchase Insmed's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Last Transaction | Type | Shares | Value | Absolute Investment Advisers Llc | 2023-06-30 | Debt | 8.5 M | 7.1 B | Vanguard Group Inc | 2023-06-30 | Common Shares | 13.3 M | 281.1 M | Blackrock Inc | 2023-06-30 | Common Shares | 10.3 M | 216.4 M | Price T Rowe Associates Inc | 2023-06-30 | Common Shares | 10.2 M | 214.6 M | T Rowe Price Investment Management Inc | 2023-06-30 | Common Shares | 8.3 M | 175.2 M | Deep Track Capital Lp | 2023-06-30 | Common Shares | 6.5 M | 137.2 M | State Street Corp | 2023-06-30 | Common Shares | 6 M | 127 M | Palo Alto Investors Lp | 2023-06-30 | Common Shares | 5.9 M | 124.3 M | Macquarie Group Ltd | 2023-06-30 | Common Shares | 4.4 M | 92.7 M | William Blair Investment Management Llc | 2023-06-30 | Common Shares | 4.3 M | 90.4 M | Fmr Llc | 2023-06-30 | Common Shares | 4.1 M | 86.2 M |
Insmed Cash Flow Accounts
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 (projected) | ||
| Capital Expenditure | (13.09 M) | (42.27 M) | (6.24 M) | (7.29 M) | (9.88 M) | (10.66 M) | |
| Depreciation Amortization and Accretion | 4.83 M | 19.94 M | 20.08 M | 26.77 M | 22.31 M | 24.07 M | |
| Net Cash Flow or Change in Cash and Cash Equivalents | 113.91 M | (7.64 M) | 45.33 M | 184.03 M | 357.25 M | 385.46 M | |
| Issuance Purchase of Equity Shares | 8.81 M | 280.77 M | 271.94 M | 291.92 M | 311.66 M | 268.25 M | |
| Net Cash Flow from Financing | 386.74 M | 285.28 M | 271 M | 612.55 M | 793.27 M | 855.9 M | |
| Net Cash Flow from Investing | (14.81 M) | (42.27 M) | (6.82 M) | (64.28 M) | (34.58 M) | (35.49 M) | |
| Net Cash Flow from Operations | (257.98 M) | (250.65 M) | (219.35 M) | (363.3 M) | (400.44 M) | (410.98 M) | |
| Effect of Exchange Rate Changes on Cash | (45 K) | (4 K) | 494 K | (933 K) | (996 K) | (1.02 M) | |
| Share Based Compensation | 26.24 M | 26.97 M | 36.16 M | 46.02 M | 57.69 M | 62.24 M |
Insmed Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Insmed or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Insmed's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Insmed stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.38 | |
β | Beta against NYSE Composite | 0.19 | |
σ | Overall volatility | 2.77 | |
Ir | Information ratio | 0.15 |
Insmed Volatility Alert
Insmed Inc has relatively low volatility with skewness of 3.34 and kurtosis of 17.88. However, we advise all investors to independently investigate Insmed Inc to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Insmed's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Insmed's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.Insmed Fundamentals Vs Peers
Comparing Insmed's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Insmed's direct or indirect competition across all of the common fundamentals between Insmed and the related equities. This way, we can detect undervalued stocks with similar characteristics as Insmed or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Insmed's fundamental indicators could also be used in its relative valuation, which is a method of valuing Insmed by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Insmed to competition |
| Fundamentals | Insmed | Peer Average |
| Return On Equity | -14.53 | -0.31 |
| Return On Asset | -0.33 | -0.14 |
| Profit Margin | (2.58) % | (1.27) % |
| Operating Margin | (2.43) % | (5.51) % |
| Current Valuation | 4.21 B | 16.62 B |
| Shares Outstanding | 143.8 M | 571.82 M |
| Shares Owned by Insiders | 1.29 % | 10.09 % |
| Shares Owned by Institutions | 98.71 % | 39.21 % |
| Number of Shares Shorted | 12.44 M | 4.71 M |
| Price to Earning | (8.70) X | 28.72 X |
| Price to Book | 48.18 X | 9.51 X |
| Price to Sales | 10.89 X | 11.42 X |
| Revenue | 245.36 M | 9.43 B |
| Gross Profit | 190.23 M | 27.38 B |
| EBITDA | (458.21 M) | 3.9 B |
| Net Income | (481.53 M) | 570.98 M |
| Cash and Equivalents | 554.87 M | 2.7 B |
| Cash per Share | 4.62 X | 5.01 X |
| Total Debt | 1.18 B | 5.32 B |
| Current Ratio | 5.93 X | 2.16 X |
| Book Value Per Share | (1.09) X | 1.93 K |
| Cash Flow from Operations | (400.44 M) | 971.22 M |
| Short Ratio | 10.06 X | 4.00 X |
| Earnings Per Share | (5.43) X | 3.12 X |
| Target Price | 42.58 | |
| Number of Employees | 736 | 18.84 K |
| Beta | 1.55 | -0.15 |
| Market Capitalization | 3.76 B | 19.03 B |
| Total Asset | 1.66 B | 29.47 B |
| Retained Earnings | (2.7 B) | 9.33 B |
| Working Capital | 1.08 B | 1.48 B |
| Current Asset | 28.15 M | 9.34 B |
| Current Liabilities | 3.89 M | 7.9 B |
Note: Sale by John Wise of 1913 shares of Insmed [view details]
About Insmed Buy or Sell Advice
When is the right time to buy or sell Insmed Inc? Buying financial instruments such as Insmed Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2020 | 2021 | 2022 | 2023 (projected) | Receivables | 16.56 M | 24.35 M | 29.71 M | 32.06 M | Inventories | 49.59 M | 67.01 M | 69.92 M | 55.48 M |
Use Investing Ideas to Build Portfolios
In addition to having Insmed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate ETFs Thematic Idea Now
Real Estate ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Real Estate ETFs theme has 62 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Insmed Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Insmed Stock analysis
When running Insmed's price analysis, check to measure Insmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insmed is operating at the current time. Most of Insmed's value examination focuses on studying past and present price action to predict the probability of Insmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insmed's price. Additionally, you may evaluate how the addition of Insmed to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Insmed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.43) | Revenue Per Share 2.043 | Quarterly Revenue Growth 0.184 | Return On Assets (0.33) | Return On Equity (14.53) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.